Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
November 6, 2024 4:05 PM EST 14% year-over-year revenue increase from combined key growth drivers:
Xywav®, Epidiolex® and Rylaze®
2024 total revenue guidance affirmed at $4.0 to $4.1 billion
Zanidatamab 2L BTC PDUFA date of November 29, 2024
Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25
DUBLIN, Nov. 6, 2024 Â /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and... More
